OPKO Health, Inc. (NYSE:OPK) will announce second quarter 2015
operating and financial results on Wednesday August 5th, after the
close of the U.S. financial markets. OPKO's senior management will
host a conference call and live audio webcast to provide a business
update and discuss its results in greater detail at 4:30 p.m. ET on
Wednesday, August 5, 2015.
The conference call will be available via phone and webcast. The
conference call dial-in information is listed below. To access the
webcast, please log on to the OPKO website at www.opko.com at least
15 minutes prior to the start of the call to ensure adequate time
for any software downloads that may be required. A link to the live
webcast is also included below.
CONFERENCE CALL & WEBCAST
INFORMATION:
WHEN: Wednesday, August 5, 2015, 4:30 p.m. ETDOMESTIC &
CANADA DIAL-IN: (888) 283-6901INTERNATIONAL DIAL-IN: (719)
457-2506
LIVE WEBCAST LINK:
http://public.viavid.com/index.php?id=115768
For those unable to participate in the conference call or
webcast, a replay will be available beginning August 5, 2015 at
7:30 p.m. ET until August 12, 2015 at 11:59 p.m. ET. To access the
replay, dial (877) 870-5176 or (858) 384-5517. The replay passcode
is 6203507.
The replay can also be accessed for a period of time on OPKO’s
website at www.opko.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics
company that seeks to establish industry leading positions in
large, rapidly growing markets by leveraging its discovery,
development and commercialization expertise and novel and
proprietary technologies.
Important Information For Investors And Shareholders
This communication does not constitute an offer to buy or sell
or the solicitation of an offer to buy or sell any securities or a
solicitation of any vote or approval. This communication relates to
a proposed business combination between Bio-Reference Laboratories,
Inc. (“Bio-Reference Laboratories”) and OPKO Health, Inc. (“OPKO”).
In connection with this proposed business combination,
Bio-Reference Laboratories and/or OPKO will file relevant materials
with the Securities Exchange Commission (the “SEC”), including an
OPKO registration statement on Form S-4, which was filed with the
SEC on July 2, 2015, was amended by Amendment No. 1 on July 15,
2015, and was declared effective on July 17, 2015, and a definitive
proxy statement/prospectus in connection with the proposed
transaction, which was filed by Bio-Reference Laboratories and OPKO
on July 20, 2015. Bio-Reference Laboratories first mailed the
definitive proxy statement/prospectus to Bio-Reference Laboratories
shareholders on July 20, 2015. INVESTORS AND SECURITY HOLDERS OF
BIO-REFERENCE LABORATORIES AND OPKO ARE URGED TO READ THE
DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT MAY
BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION.
Investors and security holders may obtain free copies of the
definitive proxy statement/prospectus and other documents filed
with the SEC by Bio-Reference Laboratories and/or OPKO through the
website maintained by the SEC at www.sec.gov. Copies of the
documents filed with the SEC by Bio-Reference Laboratories are
available free of charge on Bio-Reference Laboratories’ website at
http://www.bioreference.com or by contacting Bio-Reference
Laboratories’ Investor Relations Department by email at
tmackay@bioreference.com or by phone at (201) 791-2600. Copies of
the documents filed with the SEC by OPKO are available free of
charge on OPKO’s website at www.opko.com or by contacting OPKO’s
Investor Relations Department by email at contact@opko.com or by
phone at (305) 575-4100.
Participants in Solicitation
Bio-Reference Laboratories, OPKO, their respective directors and
certain of their respective executive officers may be considered
participants in the solicitation of proxies in connection with the
proposed transaction. Information about the directors and executive
officers of Bio-Reference Laboratories is set forth in its Annual
Report on Form 10-K for the year ended October 31, 2014, which
was filed with the SEC on January 13, 2015, its Quarterly
Report on Form 10-Q for the quarter ended April 30, 2015 which
was filed with the SEC on June 9, 2015 and its Current Reports
on Form 8-K, which were filed with the SEC on March 5,
2015, April 29, 2015, June 4,
2015, June 8, 2015, June 10, 2015 and
June 11, 2015. Information about the directors and executive
officers of OPKO is set forth in its amended Annual Report on Form
10-K for the year ended December 31, 2014, which was filed
with the SEC on February 27, 2015 and April 30, 2015, its
proxy statement for its 2015 annual meeting of stockholders, which
was filed with the SEC on May 7, 2015, its Quarterly Report on
Form 10-Q for the quarter ended March 31, 2015 which was filed
with the SEC on May 11, 2015 and its Current Reports on Form
8-K, which were filed with the SEC on March 19,
2015, June 4, 2015, June 9,
2015, June 10, 2015, June 18, 2015 and July 2,
2015.
These documents can be obtained free of charge from the sources
indicated above. Additional information regarding the participants
in the proxy solicitations and a description of their direct and
indirect interests, by security holdings or otherwise, is contained
in the definitive proxy statement/prospectus and other relevant
materials filed with the SEC.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements in this communication regarding the proposed
acquisition of Bio-Reference Laboratories by OPKO, including any
statements regarding the expected timetable for completing the
proposed transaction, synergies, benefits and opportunities of the
proposed transaction, future opportunities for the combined company
and products, future financial performance and any other statements
regarding OPKO’s and Bio-Reference Laboratories’ future
expectations, beliefs, plans, objectives, financial conditions,
assumptions or future events or performance that are not historical
facts are “forward-looking” statements made within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as
amended. The words “anticipate,” “believe,” “ensure,” “expect,”
“if,” “intend,” “estimate,” “probable,” “project,” “forecasts,”
“predict,” “outlook,” “aim,” “will,” “could,” “should,” “would,”
“potential,” “may,” “might,” “anticipate,” “likely” “plan,”
“positioned,” “strategy,” and similar expressions, and the negative
thereof, are intended to identify forward-looking statements.
All forward-looking information are subject to numerous risks
and uncertainties, many of which are beyond the control of
Bio-Reference Laboratories and OPKO, that could cause actual
results to differ materially from the results expressed or implied
by the statements. These risks and uncertainties include, but are
not limited to: failure to obtain the required vote of
Bio-Reference Laboratories’ shareholders; the timing to consummate
the proposed transaction; the risk that a condition to closing of
the proposed transaction may not be satisfied or that the closing
of the proposed transaction might otherwise not occur; the risk
that a regulatory approval that may be required for the proposed
transaction is not obtained or is obtained subject to conditions
that are not anticipated; the diversion of management time on
transaction-related issues; ability to successfully integrate the
businesses; risk that the transaction and its announcement could
have an adverse effect on Bio-Reference Laboratories’ ability to
retain customers and retain and hire key personnel; the risk that
any potential synergies from the transaction may not be fully
realized or may take longer to realize than expected; new
information arising out of clinical trial results; and the risk
that the safety and/or efficacy results of existing clinical trials
will not support continued clinical development, as well as risks
inherent in funding, developing and obtaining regulatory approvals
of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations
and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions
and litigation, among other factors. The forward-looking statements
contained in this communication may become outdated over time. OPKO
and Bio-Reference Laboratories do not assume any responsibility for
updating any forward-looking statements. Additional information
concerning these and other factors can be found in Bio-Reference
Laboratories’ and OPKO’s respective filings with the SEC and
available through the SEC’s Electronic Data Gathering and Analysis
Retrieval system at www.sec.gov, including Bio-Reference
Laboratories’ and OPKO’s most recent Annual Reports on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and
the definitive proxy statement/prospectus. The foregoing list of
important factors is not exclusive. Bio-Reference Laboratories and
OPKO assume no obligation to update or revise any forward-looking
statements as a result of new information, future events or
otherwise, except as may be required by law. Readers are cautioned
not to place undue reliance on these forward-looking statements
that speak only as of the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150730006696/en/
OPKO Health, Inc.Steven D. Rubin or Adam Logal, 305-575-4100
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024